Serum complements and immunoglobulin profiles in systemic lupus erythematosus patients: An observational study at a teaching hospital

Ranjan Singh Rana¹, Bitan Naik¹, Mahima Yadav¹, Usha Singh¹, Anup Singh², Shailja Singh¹

¹Departments of Pathology and ²Medicine, Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), Varanasi, Uttar Pradesh, India

ABSTRACT

Context: Serum complement proteins and autoantibodies play an important role in the pathogenesis and diagnosis of systemic lupus erythematosus (SLE). Abnormalities in various immunoglobulin levels are described in patients of SLE. Aims: To study the spectrum of clinical manifestations and measure the serum levels of complement C3, complement C4, autoantibodies and immunoglobulin G (IgG) in patients of SLE and compare with healthy controls. Settings and Design: The present study is a prospective hospital-based observational study conducted between May 2014 and December 2018. Statistical Analysis Used: Unpaired t-test was used to compare the mean values between the SLE patients and healthy controls. Material and Methods: A total of 100 cases of SLE and 100 healthy controls were included in the study. The clinical data were retrieved. Serum antinuclear antibody, anti-ds DNA antibody, and anti-Smith antibody levels, and complements C3, C4 and IgG were measured. Results: Arthritis (89%) and anaemia (65%) were two common clinical presentations. The low complement C3 levels and C4 were detected in 64 and 62% of the SLE patients. Serum IgG was increased in 41% of the patients. A reduced level of IgG was detected in 6% of the patients. Conclusion: Primary care physicians should be aware of the clinical and serological manifestations of SLE as early detection will reduce end-organ damage. Autoantibody testing and complement testing should be done in all suspected cases. This study showed a significantly reduced C3 and C4 and elevated IgG in many cases of SLE as compared to control. Hypogammaglobulinemia was also present in a minority of the cases.

Keywords: Complement C3, complement C4, immunoglobulin, systemic lupus erythematosus

Introduction

Systemic lupus erythematosus (SLE) is a multisystemic disease associated with the formation of autoantibodies and activation of the complement system which leads to tissue damage.¹ In India, there is a paucity of rheumatologists, while the disease burden is gradually increasing. The primary care physician should be aware of the essential serological tests like antinuclear antibody (ANA) for diagnostic purposes and complements for disease activity. Only the diagnosed patients might then be referred to tertiary care centres for treatment. The consumption of complement leads to low serum levels of C4 and C3 in SLE patients. Due to the clinical relevance of complement levels in SLE, the new classification criteria developed by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) includes low plasma complement (C3, C4, CH50) as one
of the diagnostic criteria. Hypogammaglobulinemia and hypogammaglobulinemia both were described in the SLE patients. B-cell targeted therapy with rituximab is indicated in SLE with refractory disease. A few studies advocate the measurement of serum immunoglobulin levels to detect hypogammaglobulinemia before starting B-cell targeted therapy like rituximab, as it further induces hypogammaglobulinemia. The aim of our study is to measure the serum levels of complement C3, complement C4, IgG and autoantibodies like ANA, anti-double-stranded DNA antibody (anti-dsDNA) and anti-Smith (Sm) antibody in patients of SLE and healthy controls.

Materials and Methods

The present study is a hospital-based prospective observational study conducted between May 2014 and December 2018. A total of 100 patients of SLE and 100 healthy age and sex-matched controls were included in the study. The patients who visited the rheumatology OPD units of the Department of Medicine were evaluated for SLE. In all the cases, clinical details and blood samples were taken after obtaining consent from the patients. The study was conducted after obtaining ethical approval from the Institute Ethics Committee (letter no 2014-15/EC/1193). Inclusion criteria: All patients diagnosed as SLE by the revised 1997 American College of Rheumatology (ACR) criteria were included in the study. Exclusion criteria: The patients taking immunosuppressive drugs were excluded from the study. Sample collection: Four milliliters of blood was taken in a plain vial for immunoglobulin, complement, ANA, anti-dsDNA antibody and anti-Sm antibody estimation. The serum sample was stored at -70°C.

Estimation of ANA and anti-dsDNA

Semiquantitative estimation of the serum level of antinuclear antibodies was done by an indirect non-competitive enzyme immunoassay ANA Kit of Euro Diagnostica, Sweden. The quantitative estimation of anti-dsDNA antibodies was done by an indirect non-competitive enzyme immunoassay dsDNA Kit of Euro Diagnostica, Sweden.

Complement and immunoglobulin estimation

Immage 800 protein chemistry analyser of Beckman Coulter, USA, was used for the estimation of complement and IgG by the nephelometry method. C3 and C4 estimation were done by Complement C3 and C4 Kits of Beckman Coulter. The reference range of C3 is 80–160 mg/dL and C4 is 10–40 mg/dL in our laboratory. The IgG estimation was done by Human Immunoglobulin IgG Kits of Beckman Coulter by the nephelometry method. The reference value of IgG is 600–1600 mg/dL in our laboratory. The detection of IgG autoantibodies against the Sm antigens was done by D-tek BlueDriver Dot ANA8 IgG Immunodot kit (D-tek, Mons, Belgium). The test is based on the principle of enzyme immunoassay.

Statistical analysis

All statistical analyses were performed using SPSS version 20. Unpaired t-test was performed to find the statistical significance between the mean and standard deviation of immunoglobulin, complement of patients and healthy controls. The Chi-square test was used to find out the significance between the categorical data of two groups. A P value of less than 0.05 (P < 0.05) was considered statistically significant.

Results

A majority of our patients were females (n = 82, 82%) in our study with the female: male ratio of 4.6:1. In the control group, 64 were females and 36 were males. The age-wise distribution of patients and controls is shown in Table 1. The highest number of SLE cases (37.0%) was seen in the age group of 21–30 years. The mean age of the SLE patients was 31.67 ± 10.09 years with the age range from 6 to 65 years. The frequency of various clinical features in the SLE patients is listed in Table 2. Arthritis was the most common clinical presentation (89%) of SLE in our study. Renal involvement was seen in 42% of the cases. Abnormalities in the haematological parameters were seen in 67 (67%) cases. Anaemia was present in 65 (65%) patients, followed by lymphopenia in 25 cases. Leucopenia was noted in 10 cases and thrombocytopenia in 8 cases. Haemolytic anaemia was seen in only two cases. The occurrence of ANA, anti-dsDNA antibody and anti-Sm antibody in patients and controls is shown in Table 3. In our study, 96% of the cases were positive for ANA, 32% of the cases were positive for anti-dsDNA and anti-Sm Ab was detected in only 33% of the cases. The rise of ANA, anti-dsDNA and anti-Sm antibody in SLE was statistically significant as compared to control. In healthy controls, ANA was detected in six cases while anti-dsDNA or anti-Sm Ab was not detected.

The serum levels of C3 and C4 in the SLE patients and controls are shown in Table 4. Sixty-four (64%) patients had reduced C3 levels and 36 (36%) patients had values within the normal range. The comparison between the mean values showed that the SLE patients had significantly reduced serum C3 levels as compared to controls (P-value < 0.001). The reduced value of C4 levels was detected in 62 (62.0%) SLE patients. The C4 levels were within the normal range in 38 (38.0%) cases and none of the patients had elevated C4 values. The mean value of C4 was significantly

| Table 1: Age-wise distribution of SLE patients and control |
|-----------------------------------------------|
| Age groups of patients (years) | SLE (n=100) | Control (n=100) |
|---------------------------------|------------|----------------|
| <20                            | 14 14.0    | 14 14.0        |
| 21-30                          | 37 37.0    | 63 63.0        |
| 31-40                          | 22 22.0    | 18 18.0        |
| 41-50                          | 14 14.0    | 5 5.0          |
| >50                            | 3 3.0      | 0 0.0          |
| Mean±SD                        | 31.67±10.09 | 25.95±9.17    |
Table 2: Frequency of various clinical manifestations in SLE

| Symptoms                  | SLE (n=100) n (%) |
|---------------------------|------------------|
| Malar rash                | 41 (41%)         |
| Discoid rash              | 19 (19%)         |
| Photosensitivity          | 55 (55%)         |
| Oral ulcer                | 41 (41%)         |
| Arthritis                 | 89 (89%)         |
| Pleuritis                 | 21 (21%)         |
| Pericarditis              | 2 (2%)           |
| Nephritis                 | 42 (42%)         |
| Neuropsychiatric          | 15 (15%)         |
| Haematological abnormalities| 67 (67%)        |
| Fever                     | 54 (54%)         |
| Alopecia                  | 61 (61%)         |

Table 3: Antinuclear antibody (ANA), anti-dsDNA antibody and anti-Sm antibody positivity in SLE patients and controls

| Groups                  | No (%)                  |
|-------------------------|-------------------------|
| A. Control (100)        |                         |
| Serum C4 value (mg/mL)  | Mean±SD                 |
| <80                     | 64 (6.0)                |
| 80-160                  | 36 (0.0)                |
| >160                    | 0 (0.0)                 |
| B. SLE (100)            |                         |
| Serum C4 value (mg/mL)  | Mean±SD                 |
| <10                     | 96 (96.0)               |
| 10-40                   | 32 (32.0)               |
| >40                     | 33 (33.0)               |
| A vs. B                 |                         |
| χ²                      | 162.065                 |
| P                       | <0.0001*                |
| Anti-dsDNA              |                         |
| A. Control (100)        |                         |
| Serum C3 value (mg/mL)  | Mean±SD                 |
| <80                     | 6 (6.0)                 |
| 80-160                  | 0 (0.0)                 |
| >160                    | 0 (0.0)                 |
| B. SLE (100)            |                         |
| Serum C3 value (mg/mL)  | Mean±SD                 |
| <10                     | 96 (96.0)               |
| 10-40                   | 32 (32.0)               |
| >40                     | 33 (33.0)               |
| A vs. B                 |                         |
| χ²                      | 38,095                  |
| P                       | <0.0001*                |
| Anti-Sm                 |                         |
| A. Control (100)        |                         |
| Serum C3 value (mg/mL)  | Mean±SD                 |
| <80                     | 02 (0.0)                |
| 80-160                  | 89 (89.0)               |
| >160                    | 9 (9.0)                 |
| B. SLE (100)            |                         |
| Serum C3 value (mg/mL)  | Mean±SD                 |
| <10                     | 08 (8.0)                |
| 10-40                   | 88 (88.0)               |
| >40                     | 04 (4.0)                |

Table 4: Serum complements C3 and C4 levels in SLE patients and controls

| Study group (no. of cases) | Serum C3 value (mg/mL) | Mean±SD | A vs. B | t | P |
|-----------------------------|------------------------|---------|---------|---|---|
| A. SLE (100)                | <80                    | 64       | 36      | 0 | 90.62±41.44 | 6.072 | <0.0001* |
| B. Control (100)            | <10                    | 96       | 36      | 0 | 0.0          |
| A vs. B                     |                         | χ²       | 162.065 |   | <0.0001*    |
| Study group (no. of cases)  | Serum C4 value (mg/mL) | Mean±SD | A vs. B | t | P |
| A. SLE (100)                | <10                    | 62       | 38      | 0 | 16.39±11.84 | 3.449 | 0.0007*  |
| B. Control (100)            | <10                    | 62       | 38      | 0 | 0.0          |
| A vs. B                     |                         | χ²       | 38,095  |   | <0.0001*    |

Discussion

SLE is a systemic disease which is seen in all age groups but is more common in young adults. In our study, a majority of SLE patients (69%) are between 21 and 40 years of age. The mean age of presentation is 31.47 years. The mean age of SLE patients in different studies varied from 21.6 to 31 years. Malaviya et al.[9] and Saigal et al.[7] from India reported a lower mean age of presentation: 24 and 27.9 years, respectively. Paul et al.[9] from India reported the lowest mean age of 21.6 years. Masi et al.[10] from the United States reported a mean age of 31 years which is very much close to our study. It has long been observed that SLE mostly affects females. In our study, the female to male ratio was 4.6:1. Masi et al.[10] reported a female to male ratio of 5.5:1, which is close to our study findings. In contrast to our study, other workers from India reported a much higher prevalence of SLE in females. Malaviya et al.[9] from New Delhi reported a female to male ratio of 8:1, while in the study of Saigal et al.[7] from Rajasthan, it was 11.1: Paul et al.[9] from Kerala reported a high female to male ratio of 19:1. One study from northeast India reported a very high female to male ratio of 28:1.[10] A recent Indian study in a large cohort of adult SLE patients reported the female to male ratio of 13:1.[11]

In the present study, arthritis was the most common (89%) clinical manifestation of SLE. One previous study by Paul et al.[9] found it in 89.3% of the cases. Fever was present in 54% of the cases of SLE in the present study. Similar results were seen in a study done by Madhavan et al.[12] Pattanaik et al.[11] reported a very high incidence of fever in 75.3% of adult SLE patients. Paul et al.[9] noted fever in only 4% of the patients and Saigal et al.[13] found it in 6.7% of the cases. Malar rashes were found in 41% of the cases, which was more or less similar to the findings of the previous studies.[8,12] Photosensitivity was found in 55% of the cases of SLE in the present study. Madhavan et al.[12] 1988, reported it in 52% of the cases. The oral ulcer was also a very common manifestation in SLE. In the present study, it was found in 41% of the cases but Saigal et al.[13] and Paul et al.[9] found it in 64 and 61% of the cases, respectively. Malaviya et al.[9] and Madhavan et al.[12] found it in low frequency. Pleuritis was noted in 21% of the SLE cases in the present study, while the other studies reported it in a low frequency varying from 8 to 17%.[8,10,12] Alopecia was observed in 62% of the SLE cases, which was more or less similar to the findings of other studies.[7,9] Malaviya et al.[9] reported alopecia in a very high frequency (82%) in the SLE patients. Nephritis was observed in 42% of the cases in our study but Malaviya et al.[9] reduced in SLE (P-value 0.001) as compared to controls. The correlation between serum C3 and C4 levels with the gender of the patients is shown in Table 5. There was no significant difference in the mean serum C3 and C4 in the female and male patients of SLE, although more percentage of female patients had reduced C3 levels (65.9%) as compared to males (55.6%).
found it in 73.1% of the cases, which was higher than the present study. Madhavan et al.\(^\text{[15]}\) found it in 38.8% of the cases and Paul et al.\(^\text{[19]}\) reported it in 33.3% of the cases. Joo et al.\(^\text{[11]}\) reported renal involvement in 42% of the patients in a study of a large Asian cohort. Pattanaik et al.\(^\text{[12]}\) reported nephritis in 48.6% of the adult SLE patients. The neuropsychiatric manifestation was noted in 15% of the cases. Findings similar to our study were seen in one previous study.\(^\text{[10]}\) The haematological abnormalities were detected in 67% of the cases. Anaemia was the most frequent haematological abnormality (65%). A similar proportion of haematological abnormalities was seen in a study by Talukdar et al.\(^\text{[19]}\). In the present study, anaemia is the second most common clinical presentation of SLE. Anaemia due to iron deficiency is also quite prevalent in the young Indian female population. So the primary care provider should be alert, otherwise, the diagnosis of SLE can be missed.

The incidence of ANA in the general healthy population varies from 5.92% in the Chinese population to 30.8% in the Afro-American population.\(^\text{[14,15]}\) Our study results (6%) are close to a study done in the Chinese population. This 6% of healthy controls, which were positive for ANA had no clinical symptoms. It is important for the primary care physician to be aware of the fact that antinuclear antibodies can be seen in normal healthy individuals as found in the present study. The diagnosis of SLE should not be suspected only on the basis of a positive ANA test, in the absence of clinical symptoms. Similarly, ANA can be negative in the case of lupus due to multiple reasons like technical limitations, immune-complex-bound ANA or prozone effect. So, if the clinical features of SLE are present with negative ANA, the primary care physician can still suspect SLE, and they can later repeat the antibody tests in follow up. The presence of ANA is the immunological hallmark of SLE. In clinical practice, ANA testing is often used as a part of primary investigation. ANA positivity in an SLE patient varies from 93.3 to 100\%\(^\text{[6,8,10,16]}\). In our study, we also found 96% anti-ANA positivity in SLE patients. Two recent studies, one from Greece and the other from Korea reported 97.3% and 97.8% ANA positivity in the SLE patients.\(^\text{[17,18]}\) Anti-dsDNA antibodies were detected in 32% of the cases in our study. In different studies, the frequency of anti-dsDNA varied from 43 to 92%, with the specificity varying from 89 to 99\%\(^\text{[12,19‑23]}\). These authors also found that anti-dsDNA correlates with disease activity. In contrast to these studies, we found a very low frequency (32\%) of anti-dsDNA positivity. Similar to our findings, Faria et al.\(^\text{[24]}\) from Brazil reported the frequency of anti-dsDNA in 32% and Nikolopoulos et al.\(^\text{[27]}\) reported it in 36.6% of the patients. Anti-Sm antibodies are present in 15–55.5% of the cases of SLE patients.\(^\text{[19,20,23,26]}\) The frequency of anti-Sm Ab varies from 21 to 35% in different Indian studies.\(^\text{[6,10,12]}\) In the present study, we found positivity in 33% of the cases. A wide variation in the presence of anti-dsDNA and anti-Sm antibodies is due to the different techniques used for the detection of these antibodies. The main utility of the anti-Sm antibody is in the diagnosis of SLE when the anti-dsDNA antibody is absent. It has been observed that in around 14.8% of the SLE cases, where anti-dsDNA antibody was absent but anti-Sm antibody was present, thus, confirming SLE.\(^\text{[27]}\) Similarly, in our study, 15% of the SLE patients had anti-Sm antibody but anti-ds DNA antibody was absent. The above findings of our study suggest that when a primary care physician has a strong clinical suspicion of SLE but the ANA is negative, in those cases, the anti-dsDNA and anti-Sm antibodies may help in the diagnosis. The primary care physician may keep these suspected SLE patients with negative ANA in the follow-up and the ANA can be repeated later with different kits and techniques.

### Table 5: Correlation of serum complements C3 and C4 levels with gender in SLE patients

| Gender of SLE patients | Serum C3 value (mg/dL) | Mean±SD | A vs. B | t | P |
|------------------------|------------------------|---------|---------|---|---|
|                        | <80                    | 80-160  | >160    |   |   |
| A. Female (82)         | No                     | 54      | 28      | 0 | 88.46±41.63 | 1.115 | 0.268 |
|                        | %                      | 65.9    | 34.1    | 0 |   |   |
| B. Male (18)           | No                     | 10      | 8       | 0 | 100.47±40.27 |   |   |
|                        | %                      | 55.6    | 44.4    | 0 |   |   |

### Table 6: Serum IgG levels in SLE patients and controls

| Study group (no. of cases) | Serum IgG levels (mg/dL) | Mean±SD | A vs. B | t | P |
|---------------------------|--------------------------|---------|---------|---|---|
|                           | <600                     | 600-1600| >1600   |   |   |
| A. SLE (100)              | n                        | 08      | 51      | 41 | 1811.27±1401.38 | 4.117 | <0.0001* |
|                           | %                        | 8.0     | 51.0    | 41.0 |   |   |
| B. Control (100)          | n                        | 00      | 100     | 00 | 1230.94±151.63 |   |   |
|                           | %                        | 0.0     | 100.0   | 0.0 |   |   |

*Statistically significant (P<0.05)

### Table 7: Correlation of IgG levels with gender in SLE patients

| Gender of SLE patients | Serum IgG value (mg/dL) | Mean±SD | A vs. B | t | P |
|------------------------|-------------------------|---------|---------|---|---|
|                        | <600                    | 600-1600| >1600   |   |   |
| A. Female (82)         | n                       | 5       | 46      | 31 | 1784.71±1449.97 | 0.403 | 0.688 |
|                        | %                       | 6.1     | 56.1    | 37.8 |   |   |
| B. Male (18)           | n                       | 3       | 5       | 10 | 1932.27±1183.32 |   |   |
|                        | %                       | 16.7    | 27.8    | 55.6 |   |   |
In the present study, reduced levels of C3 were detected in 64.0% of the cases and C4 was reduced in 62.0% of the cases of SLE. Jallouli et al.\(^\text{[22]}\) also found C3 deficiency in 63.5% and C4 in 73.4% of the patients of SLE. Elwy et al.\(^\text{[29]}\) and Li et al.\(^\text{[29]}\) also reported the mean levels of C3 and C4 significantly reduced in SLE as compared to healthy controls. The present study findings further confirm that a simple serological test like the measurement of serum complements helps in the diagnosis of SLE by the primary care physician.

In our study, 41 (41%) patients had IgG levels above 1600 mg/dL. The mean level of IgG was significantly elevated in SLE patients compared to healthy controls. Many previous studies have also reported an increased level of IgG in SLE patients.\(^\text{[3,30,31]}\) In our study, we also found eight (8%) patients with hypogammaglobulinemia (IgG <600 mg/dL). A study by Cuadrado et al.\(^\text{[28]}\) also observed reduced IgG level in 8.4% of the SLE patients. B-cell targeted therapy with rituximab can itself cause hypogammaglobulinemia in SLE patients with normal pretreatment immunoglobulin levels and increase the risk of infection. In SLE patients with reduced levels of immunoglobulins before treatment, rituximab can further reduce the immunoglobulins and potentially increase the risk of infection. Therefore, it is important to estimate the serum IgG levels in the SLE patient before starting the therapy with rituximab.

Limitations: The demographic data of the study cannot be generalised, since it is a single-centre study with a limited sample size.

**Conclusion**

Our study reveals that arthritis and anaemia are the two most common clinical manifestations of SLE. Antinuclear antibodies can be seen in normal healthy individuals. Hence, the diagnosis of SLE should not be suspected only on the basis of a positive ANA test in the absence of clinical symptoms. Anti-smith antibody is diagnostically helpful in SLE, especially in those cases which are negative for anti-dsDNA antibodies. In our study, serum complement C3 and complement C4 levels were significantly reduced in the SLE patients. This further establishes the role of complements in the pathogenesis of SLE and tissue injury. The complements are not only useful in the diagnosis of SLE, but they can also alert the physician towards disease progression. None of the patients included in the study had received immunosuppressive treatment, and serum immunoglobulin IgG was elevated in many of them. It suggests that SLE is associated with the activation of B-lymphocytes, which leads to increased production of serum IgG. Around 8% of the patients in our study had low serum IgG levels, so we cautiously measure pretreatment immunoglobulin levels to rule out hypogammaglobulinemia in the patients of SLE before starting B-cell targeted therapy.

**Key messages**

Apart from nephritis and arthritis, anaemia is also a very common presentation of SLE.

ANA positivity can be seen in some healthy individuals so indiscriminate ANA testing should be avoided.

In patients with clinical suspicion of SLE and negative ANA, the physician should repeat antibody tests on follow-up as not all features of SLE will appear simultaneously.

Reduction of serum complements C3 and C4 is seen in many patients of SLE. Routine measurement of serum complements helps in diagnosis and predicting flare-ups of SLE.

Both elevated and reduced levels of serum IgG were detected in SLE. The measurement of serum IgG should be done before starting B-cell targeted therapy to rule out hypogammaglobulinemia.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers 2016;2:16039.
2. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400-12.
3. Cuadrado MJ, Calatayud I, Urquizu-Padilla M, Wijetilleka S, Kiani-Alikhan S, Karim MY. Immunoglobulin abnormalities are frequent in patients with lupus nephritis. BMC Rheumatol 2019;3:30.
4. Almaghlouth I, Johnson SR, Pullenayegum E, Gladman D, Urowitz M. Immunoglobulin levels in systemic lupus erythematosus: A narrative review. Lupus 2021;30:867-75.
5. Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 2018;1:e184169.
6. Malaviya AN, Singh RR, Kumar A, De A, Kumar A, Aradhye S. Systemic lupus erythematosus. Nat Rev Dis Primers 2016;2:16039.
Systemic lupus erythematosus in northern India: A review of 329 cases. J Assoc Physicians India 1988;36:476-80.

7. Saigal R, Kansal A, Mittal M, Singh Y, Maharia HR, Juneja M. Clinical profile of systemic lupus erythematosus patients at a tertiary care centre in Western India. J Indian Acad Clin Med 2011;13:27-32.

8. Paul BJ, Fassaludeen M, Nandakumar, Razia MV. Clinical profile of systemic Lupus Erythematosus in northern Kerala. J Indian Rheumatol Assoc 2003;11:94-7.

9. Masi AT, Kaslow RA. Sex effects in systemic lupus erythematosus: A clue to pathogenesis. Arthritis Rheum 1978;21:480-4.

10. Talukdar D, Gogoip AO, Doley D, Marak RR, Kakati S, Pradhan V, et al. The clinical and immunological profiles of systemic lupus erythematosus patients from Assam, North-East India. Indian J Rheumatol 2020;15:181-6.

11. Pattanaik SS, Muhammed H, Chatterjee R, Naveen R, Lawrence A, Agarwal V, et al. In-hospital mortality and its predictors in a cohort of SLE from Northern India. Lupus 2020;29:1971-7.

12. Madhavan R, Porkodi R, Ramakrishnan S, Krishnamurthy V, Partibhan M, Chandrasekaran AN. Systemic Lupus Erythematosus - The Madras Experience. J Assoc Phys India 1988;36:481-4.

13. Joo YB, Bae SC. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: Comparison with other Asian populations. Int J Rheum Dis 2015;18:117-28.

14. Wang N, Shen N, Vyse TJ, Anand V, Gunnarson I, Sturfelt G, et al. Selective IgA deficiency in autoimmune diseases. Mol Med 2011;17:1383-96.

15. Wandstrat AE, Carr-Johnson F, Branch V, Gray H, Fairhurst AM, Reimold A, et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun 2006;27:153-60.

16. Hietarinta M, Lassila O. Clinical significance of autoantibodies in systemic rheumatic diseases. Ann Med 1996;28:283-91.

17. Nikolopoulou D, Kostopoulou M, Pieta A, Karageorgas T, Tseronis D, Chavatza K, et al. Evolving phenotype of systemic lupus erythematosus in Caucasians: Low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the ‘Attikon’ cohort. Lupus 2020;29:514-22.

18. Koh JH, Park EK, Lee HN, Kim Y, Kim GT, Suh YS, et al. Clinical characteristics and survival of 413 patients with systemic lupus erythematosus in south eastern areas of South Korea: A multicenter retrospective cohort study. Int J Rheum Dis 2020;23:92-100.

19. Boey ML, Peebles CL, Tsay G, Feng PH, Tan EM. Clinical and autoantibody correlations in Orientals with systemic lupus erythematosus. Ann Rheum Dis 1988;47:918-23.

20. Ghedira I, Sakly W, Jeddri M. Caracteristiquescliniques et serologiques du lupus erythematexsystermique: A propos de 128 cas [Clinical and serological characteristics of systemic lupus erythematosus: 128 cases]. PatholBioIbl(Paris) 2002;50:18-24.

21. Al-Maini MH, El-Ageb EM, Al-Wahbaib SS, Al-Farsi Y, Richens ER. Demographic, autoimmune, and clinical profiles of patients with systemic lupus erythematosus in Oman. Rheumatol Int 2005;23:186-91.

22. Jallouli M, Frigui M, Hmida MB, Marzouk S, Kaddour N, Bahloul Z. Clinical and immunological manifestations of systemic lupus erythematosus: Study on 146 south Tunisian patients. Saudi J Kidney Dis Transpl 2008;19:1001-8.

23. Didier K, Bolkó L, Giusti D, Toquet S, Robbins A, Antonicelli F, et al. Autoantibodies associated with connective tissue diseases: What meaning for clinicians? Front Immunol 2018;9:541.

24. Faria AC, Barcellos KS, Andrade LE. Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus. J Rheumatol 2005;32:1267-72.

25. Wang CJ, Ooi L, Wang F. Prevalence and clinical significance of antibodies to ribonucleoproteins in systemic lupus erythematosus in Malaysia. Br J Rheumatol 1996;35:129-32.

26. Bortolini MFF, Pereira VP, Gomes Dos Santos TA, Nishara R, Skare TL. Systemic lupus erythematosus in children and adults: A retrospective study in Brazilian patients. Lupus 2021;30:1197-202.

27. Flechsig A, Rose T, Barkhudarova F, Strauss R, Klotsche J, Dähnrich C, et al. What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. Clin Exp Rheumatol 2017;35:598-606.

28. Elwy MA, Galal ZA, Hasan HE. Immunoinflammatory markers and disease activity in systemic lupus erythematosus: Something old, something new. East Mediterr Health J 2010;16:893-900.

29. Li W, Li H, Song W, Hu Y, Liu Y, DA R, et al. Differential diagnosis of systemic lupus erythematosus and rheumatoid arthritis with complements C3 and C4 and C-reactive protein. Exp Ther Med 2013;6:1271-6.

30. Cass RM, Mongan ES, Jacox RF, Vaughan JH. Immunoglobulins G, A, and M in systemic lupus erythematosus. Relationship to serum complement titer, latex titer, antinuclear antibody, and manifestations of clinical disease. Ann Intern Med 1968;69:749-56.

31. Saiki O, Saeki Y, Tanaka T, Doi S, Hara H, Negoro S, et al. Development of selective IgM deficiency in systemic lupus erythematosus patients with disease of long duration. Arthritis Rheum 1987;30:1289-92.